Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate’s biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op infections in hip, knee and shoulder.
The combined businesses will benefit from industrial and R&D synergies, including biomaterials expertise. All present management teams and operations will remain in place.
Demetra employees will number ~140, operating in >70 countries.
Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate's biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op...
Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate’s biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op infections in hip, knee and shoulder.
The combined businesses will benefit from industrial and R&D synergies, including biomaterials expertise. All present management teams and operations will remain in place.
Demetra employees will number ~140, operating in >70 countries.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
